Abstract
An HPLC method using reverse phase chromatography is presented for the quantitative determination of 1,4-Dihydroxy-5,8 Bis [[2-[(2-Hydroxyethyl) amino] ethyl] amino] 9,10 - anthracenedione in serum and urine at levels which are expected to be found in clinical trials of this drug.